Skip to search formSkip to main contentSkip to account menu

Pipobroman

Known as: Piperazine, 1,4-bis(3-bromo-1-oxopropyl)-, Pipobroman [Chemical/Ingredient] 
A piperazine derivative with potential antineoplastic alkyating activity. Although the exact mechanism of action of pipobroman has yet to be fully… 
National Institutes of Health

Related topics

Related topics

15 relations
Alkylating Activity [MoA]Drug AllergyIn BloodNeutropenia

Broader (1)

Antineoplastic Agents, Alkylating

Narrower (1)

Vercyte

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Therapy-associated leukemic transformation in myeloproliferative neoplasms - What do we know?
2008
2008
Long-Term Outcome in Polycythemia Vera (PV): Final Analysis of a Randomized Trial Comparing Hydroxyurea (HU) to Pipobroman (Pi).
Background: Only 4 randomized clinical trials in PV have directly compared cytoreductive therapies (32P, busulfan, chlorambucil… 
2001
2001
ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia.
Hydroxyurea (HU) has been used for more than 10 years in children severely affected with sickle cell disease (SCD) to reduce the… 
2001
2001
Carcinomes cutanés et buccaux multiples après traitement par l'hydroxyurée
Introduction. Les effets secondaires cutanes de l'hydroxyuree sont frequents. Le plus grave est la survenue de cancers cutanes… 
2000
2000
Leukemia and Myelodysplasia Effect of Multiple Cytotoxic Therapy in Essential Thrombocythemia
Essential thrombocythemia (ET) is a chronic myeloproliferative disorder characterized by increased risk of thrombosis and/or… 
1998
1998
4 Treatment of polycythaemia vera and essential thrombocythaemia
1996
1996
Myelodysplastic transformation in a case of essential thrombocythemia treated with pipobroman.
Essential thrombocythemia (ET) is a clonal disorder of the myeloid stem cell that causes pathologic expansion of the… 
1993
1993
Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
The present report is based on an analysis of the evolution of 720 cases of Polycythaemia vera treated with pipobroman and 624… 
1992
1992
[Treatment of polycythemia vera with hydroxyurea or pipobroman. Efficacy and toxicity analysed from a protocol of 96 patients under 65 years of age. Le Groupe d'Etude des Polyglobulies].
  • Y. Najean
  • Presse medicale
  • 1992
  • Corpus ID: 13229785
Between 1980 and 1991, 96 patients with documented polycythemia vera were treated by hydroxyurea or pipobroman, according to a… 
1984
1984
Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients.
Pipobroman (PB) was tested in a prospective efficacy trial in 24 previously untreated patients with essential thrombocythemia and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)